Ioannidou-Papayannaki E, Lefkos N, Boudonas G, Efthimiadis A, Psirropoulos D, Vogas V, Papadopoulos I, Klonizakis I
Haematology Laboratory of 2nd Dept. of Internal Medicine, Aristotelian University of Thessaloniki, Hippokration Hospital, Greece.
Acta Cardiol. 2000 Aug;55(4):247-53. doi: 10.2143/AC.55.4.2005747.
The purpose of this study was to evaluate the changes in tissue-plasminogen activator (t-PA), plasminogen activator inhibitor - type 1 (PAI-1) and D-dimer (DD) antigen plasma levels in acute myocardial infarction (AMI) patients after thrombolytic therapy with two different thrombolytic agents, rt-PA or acetyl-streptokinase and to find out any correlation between the plasma t-PA, PAI-1 and DD levels with the infarct size as it is estimated from the peak of serum CPK levels. The plasma antigen levels of t-PA, PAI-1 and DD were measured by the enzyme immunoassay method (Stago), in 57 consecutive patients (M = 46, F = 11, mean age 55.6 +/- 8.8 years) and in 25 normal subjects (M = 18, F = 7, mean age 54.0 +/- 5.5 years). In 47 out of the 57 patients who were treated successfully with 100 mg of rt-PA (26 patients) or with 1.5 MU 21 of acetyl-streptokinase, as well as in 10 patients who were not treated, samples were obtained again 4 and 24 hours after the end of thrombolytic therapy or admission, respectively. During the acute phase of myocardial infarction the t-PA, PAI-1 and DD antigen plasma levels were significantly higher than in healthy people. There were no significant changes in the t-PA, PAI-1 and DD plasma levels of the patients who were not treated with a thrombolytic agent. We found a significant elevation of t-PA (p < 0.001), PAI-1 (p < 0.05) and DD (p < 0.001) after 4 hours in comparison with the baseline (at presentation, before therapy). After 24 hours the t-PA and DD plasma levels remained significantly higher (p < 0.001) while the PAI-1 plasma levels returned to the pre-therapy levels. There were no significantly different changes in the t-PA, PAI-1 and DD plasma levels of either group of patients, treated with rt-PA or acetyl-streptokinase while the t-PA and PAI-1 levels were positively correlated with infarct size as estimated from peak serum CPK levels.
本研究的目的是评估急性心肌梗死(AMI)患者在使用两种不同溶栓药物(重组组织型纤溶酶原激活剂(rt-PA)或乙酰化链激酶)进行溶栓治疗后,血浆组织型纤溶酶原激活剂(t-PA)、纤溶酶原激活剂抑制剂-1(PAI-1)和D-二聚体(DD)抗原水平的变化,并找出血浆t-PA、PAI-1和DD水平与根据血清肌酸磷酸激酶(CPK)峰值估算的梗死面积之间的相关性。采用酶免疫测定法(Stago)测定了57例连续患者(男性46例,女性11例,平均年龄55.6±8.8岁)和25例正常受试者(男性18例,女性7例,平均年龄54.0±5.5岁)的血浆t-PA、PAI-1和DD抗原水平。在57例患者中,47例成功接受了100mg rt-PA(26例患者)或1.5MU乙酰化链激酶治疗,另外10例未接受治疗,分别在溶栓治疗结束后4小时和24小时或入院后再次采集样本。在心肌梗死急性期,t-PA、PAI-1和DD抗原血浆水平显著高于健康人。未接受溶栓药物治疗的患者,其血浆t-PA、PAI-1和DD水平无显著变化。与基线水平(就诊时,治疗前)相比,4小时后t-PA(p<0.001)、PAI-1(p<0.05)和DD(p<0.001)显著升高。24小时后,t-PA和DD血浆水平仍显著升高(p<0.001),而PAI-1血浆水平恢复到治疗前水平。接受rt-PA或乙酰化链激酶治疗的两组患者,其血浆t-PA、PAI-1和DD水平的变化无显著差异,而t-PA和PAI-1水平与根据血清CPK峰值估算的梗死面积呈正相关。